Covance Drug Development (a LabCorp company) has relocated its clinical research unit (CRU) in Dallas, TX, to a new, 55,000 sq.-ft., fit-for-purpose clinical research facility. The newly opened unit has expanded from 72 to 100 beds and is located in the same building as the prior unit. Also, a LabCorp patient service center will be co-located in the CRU, where patients will have an opportunity to learn more about volunteering and participating in early stage trials. The CRU includes a cGMP p...